ClinicalTrials.gg
Active, not recruitingNCT05079282Updated Sep 29, 2026

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

A Phase 1 interventional study of ONO-4685 in Relapsed or Refractory T Cell Lymphoma, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Primary conditionLymphoma, T-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, T-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, T-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Sep 29, 2026Now Active, not recruiting1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
217
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 173 studies in Lymphoma, T-Cell with a site in United States — 35 open to participants now, 51 under way, 2 of them phase 3. Lymphoma, T-Cell · United States.

Planned enrollment
9th of 166
217 · median 33
Started
2021
with 6 others
Phase 1
69 of 173
12 open now
Primary completion
2027-08
later than 16 of 50 live
Registered
140th of 173
by date

Among the 173 studies in Lymphoma, T-Cell with a site in United States, this one is the 9th largest by planned enrollment of the 166 interventional ones that give a count, is one of 7 that started in 2021, is one of 69 in phase 1, reaches primary completion later than 16 of the 50 other live ones, and was the 140th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

35 of the 173 studies in Lymphoma, T-Cell with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Lymphoma, T-Cell studies recruiting now, 41 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Lymphoma, T-Cell with a site in United States, or all of them as a file.
02

Study summary

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

03

Conditions studied

  • Relapsed or Refractory T Cell Lymphoma

Browse trials for

Keywords

  • ONO-4685
  • PD-1
  • CD3
  • Bispecific antibody
  • PTCL
  • AITL
  • PTCL-NOS
  • nodal PTCL with TFH
  • FTCL
  • CTCL
  • MF
  • SS
04

In context

Lymphoma, T-Cell Reclassified

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

This study's planned enrollment of 217 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.

Browse Lymphoma, T-Cell studies →

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Compared within Lymphoma, T-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 18 years at time of screening
  2. Written by the patient or the patients' legally authorized representative prior to screening
  3. Patients with or cytologically confirmed diagnosis of one of the following subtypes of T-cell lymphoma:

    1. Peripheral T-cell lymphoma (PTCL): Angioimmunoblastic T-cell lymphoma (AITL), PTCL, not otherwise specified (PTCL-NOS), nodal PTCL with T-follicular helper (TFH) and follicular T-cell lymphoma (FTCL)
    2. Cutaneous T-cell lymphoma (CTCL) (stages II-B, III, and IV): Mycosis fungoides (MF) and Sezary syndrome (SS)
  4. Patients must have received at least 2 prior systemic therapies
  5. Patients with PTCL must have at least 1 (Cheson BD, 2014)
  6. Patients with CTCL must have assessable disease by response criteria for CTCL (Olsen EA, 2011)
  7. Performance Status (ECOG PS) = 0-2
  8. of at least 3 months
  9. Adequate bone marrow, renal and hepatic functions

Exclusion criteria

Exclusion Criteria:

  1. Patients with central nervous system (CNS) involvement
  2. Patients with Adult T-cell leukemia/lymphoma (ATLL)
  3. Prior stem cell transplant
  4. Prior treatment with ONO-4685, , anti-PD-L1, anticytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  5. Prior allogeneic and autologous chimeric antigen receptor (CAR) T-cell therapy
  6. Patients with (other than T-cell lymphoma) except for completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, or any other malignancies that has not for at least 2 years
  7. History of severe allergy or to any monoclonal antibodies, other therapeutic proteins or (e.g., dexamethasone)
  8. History of infection with Mycobacterium tuberculosis within 2 years prior to the first dose of study treatment
  9. Patients with systemic and active infection including (HIV), or C virus infection
  10. Patients not recovered to Grade 1 or stabilized from the adverse effects (excluding alopecia) of any prior therapy for their malignancies
  11. Women who are pregnant or lactating
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (estimated)

Study arms

  • Experimental
    ONO-4685 monotherapy

    Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy

    Drug: ONO-4685

Interventions

  • ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed

07

What researchers measure

Primary outcomes

  1. Incidence, nature, and severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs).

    Adverse events with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 used as a guide for the grading of severity.

    Time frame: Through study completion, an average of 1 year

  2. Estimate of Maximum Tolerate Dose (MTD)

    MTD will be estimated based on Dose limiting toxicity (DLT) observed during the first 3 weeks of treatment

    Time frame: Up to 3 weeks

Secondary outcomes

  1. Plasma Concentration of ONO-4685

    Plasma concentration will be assessed to evaluate Pharmacokinetics

    Time frame: Up to 48 weeks

  2. Plasma Concentration of Anti-Drug Antibody (ADA)

    ADA to ONO-4685 will be assessed to evaluate potential immunogenicity.

    Time frame: Up to 48 weeks

  3. Antitumor Activity of ONO-4685

    Antitumor Activity of ONO-4685 will be assessed according to the response criteria for Lymphoma.

    Time frame: Through study completion, an average of 1 year

08

Study locations

21 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Aug 2027, 68 months after the start.

Of 59 phase 1 interventional studies under Lymphoma, T-Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 99. This study's planned 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2021
First posted
Oct 15, 2021
StartActual
Dec 10, 2021
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 29, 2026
Sites
1 site added
Show site
  • Fred Hutchinson Cancer Center · Seattle, United States
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Active, not recruiting
    1 site added
    Show site
    • Fred Hutchinson Cancer Center · Seattle, United States
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05079282
Responsible party
Sponsor
First posted
Oct 15, 2021
Start date
Dec 10, 2021
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Besufetamig

Start the discussion